Novartis Ag (NVS) Other Non Operating Income (2009 - 2026)
Novartis Ag (NVS) posted Other Non Operating Income of -$50.0 million for Q1 2026, up 45.65% sequentially from -$92.0 million in Q4 2025, and down 394.12% YoY from $17.0 million in Q1 2025.
Novartis Ag (NVS) Other Non Operating Income (2009 - 2026) Analysis & Trends
Novartis Ag (NVS) has 15 years of Other Non Operating Income data on file, last reported at -$50.0 million in Q1 2026.
- Quarterly Other Non Operating Income fell 394.12% year-over-year to -$50.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$203.0 million (down 234.44% YoY) and the FY2025 annual result came in at -$136.0 million, down 197.14% from the prior year.
- Other Non Operating Income improved to -$50.0 million in Q1 2026 per NVS's latest filing, from -$92.0 million in the prior quarter.
- The five-year high for Other Non Operating Income was $104.0 million in Q1 2023, with the low at -$92.0 million in Q4 2025.
- Average Other Non Operating Income over 5 years is $12.2 million, with a median of $17.0 million recorded in 2025.
- Year-over-year, Other Non Operating Income jumped 431.25% in 2023 and plunged 394.12% in 2026.
- Novartis Ag's Other Non Operating Income stood at $24.0 million in 2022, then decreased by 25.0% to $18.0 million in 2023, then soared by 83.33% to $33.0 million in 2024, then tumbled by 378.79% to -$92.0 million in 2025, then soared by 45.65% to -$50.0 million in 2026.
- Business Quant data shows NVS's Other Non Operating Income at -$50.0 million in Q1 2026, -$92.0 million in Q4 2025, and -$20.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -92.00 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -41.00 Mn |
| Mar 31, 2025 | 17.00 Mn |
| Dec 31, 2024 | 33.00 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 18.00 Mn |
| Sep 30, 2023 | 15.00 Mn |
| Jun 30, 2023 | 85.00 Mn |
| Mar 31, 2023 | 104.00 Mn |
| Dec 31, 2022 | 24.00 Mn |
| Sep 30, 2022 | -28.00 Mn |
| Jun 30, 2022 | 16.00 Mn |
| Mar 31, 2022 | 20.00 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -24.00 Mn |
| Jun 30, 2021 | -11.00 Mn |